Cytisine

Drug Profile

Cytisine

Alternative Names: Tabex

Latest Information Update: 25 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sopharma
  • Developer Achieve Life Sciences
  • Class Alkaloids; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • Phase III Smoking withdrawal

Most Recent Events

  • 16 Aug 2017 Clinical trials in Smoking withdrawal in USA (PO)
  • 16 Aug 2017 Achieve Life Sciences plans a clinical pharmacokinetic/pharmacodynamic trial for Smoking withdrawal in the fourth quarter of 2017
  • 10 Aug 2017 US FDA accepts IND application for cytisine for Smoking withdrawal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top